纳武单抗和伊匹单抗联合治疗转移性黑色素瘤后出现低眼压和前葡萄膜炎：一例报告
Hypotony and Anterior Uveitis following Dual Therapy with Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report.
作者信息
Patil Nikhil S, Dudok David, Khimdas Sarit
机构信息
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Ophthalmology, McMaster University, Hamilton, Ontario, Canada.
出版信息
J Curr Ophthalmol. 2024 Mar 29;35(3):294-296. doi: 10.4103/joco.joco_21_23. eCollection 2023 Jul-Sep.
PURPOSE
To describe a rare case of hypotony and anterior uveitis following dual therapy with nivolumab and ipilimumab for metastatic melanoma.
METHODS
Case report.
RESULTS
Here, we present the case of a 64-year-old man taking nivolumab and ipilimumab dual therapy for BRAF+ (v-raf murine sarcoma viral oncogene homolog B1) metastatic melanoma. After treatment for 3 months, he presented to the ophthalmology clinic with bilateral intraocular pressures of 1 mmHg, bilateral keratic precipitates, cataracts, posterior synechiae, and anterior chamber inflammation. He improved with topical medications and the cessation of immunotherapy.
CONCLUSIONS
Immunotherapies are a novel class of chemotherapy that has increased in prevalence for the treatment of numerous malignancies. There are many rare complications from these medications that are sparsely reported. Knowledge of ocular hypotony as a potential consequence of nivolumab and ipilimumab is important, particularly as it may arise months after treatment initiation and necessitate immunotherapy cessation.
目的
描述1例在接受纳武单抗和伊匹单抗联合治疗转移性黑色素瘤后出现低眼压和前葡萄膜炎的罕见病例。
方法
病例报告。
结果
在此，我们报告1例64岁男性，因BRAF+（v-raf鼠肉瘤病毒癌基因同源物B1）转移性黑色素瘤接受纳武单抗和伊匹单抗联合治疗。治疗3个月后，他因双眼眼压1 mmHg、双眼角膜后沉着物、白内障、虹膜后粘连和前房炎症就诊于眼科门诊。经局部用药和停止免疫治疗后病情好转。
结论
免疫疗法是一类新型化疗药物，在多种恶性肿瘤治疗中的应用日益普遍。这些药物有许多罕见并发症，相关报道较少。了解纳武单抗和伊匹单抗可能导致的眼压降低这一潜在后果很重要，尤其是它可能在治疗开始数月后出现，并需要停止免疫治疗。
Zotero 插件